Luminor Medical Technologies Inc. announced a corporate update which includes the plan for additional revenue streams in the diabetes sector, the amendment of its secured loans and the addition of Chief Executive Officer, Christian Sauvageau to the Board of Directors.

The Company has entered into amending agreements to transfer its CAD 1,611,334 in secured loans from Luminor Medical to Scout Corp. The Loans are secured through a general security agreement against Scout Corp. and the security interest against Luminor Medical has been discharged. The maturity date has been extended from a current obligation to $300,000 due on December 31, 2018, $400,000 due on December 31, 2019, $600,000 due on December 31, 2020 and $311,334 plus all accrued interest and any other amounts due on December 31, 2021. The principal and interest payments will be accelerated based on payments of 10% of all gross sales on Scout Corp. Assets.